Related references
Note: Only part of the references are listed.Follow-up study of MS patients treated with high-dose intravenous methylprednisolone
S. T. F. M. Frequin et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Optimal reference population for the multiple sclerosis functional composite
R. J. Fox et al.
MULTIPLE SCLEROSIS (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta
DR Smith et al.
MULTIPLE SCLEROSIS JOURNAL (2005)
Effect of mitoxantrone on MRI in progressive MS - Results of the MIMS trial
H Krapf et al.
NEUROLOGY (2005)
The multiple sclerosis functional composite: different practice effects in the three test components
A Solari et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS
M Clanet et al.
NEUROLOGY (2002)
An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS
PA Calabresi et al.
NEUROLOGY (2002)
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
R Zivadinov et al.
NEUROLOGY (2001)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial
JA Cohen et al.
ARCHIVES OF NEUROLOGY (2001)
Intrarater and interrater reliability of the MS functional composite outcome measure
JA Cohen et al.
NEUROLOGY (2000)